Abstract:Escherichia coli Nissle 1917 (EcN) is a probiotic bacterium, commonly employed to treat certain gastrointestinal disorders. It is fast emerging as an important target for the development of therapeutic engineered bacteria, benefiting from the wealth of knowledge of E. coli biology and ease of manipulation. Bacterial synthetic biology projects commonly utilize engineered plasmid vectors, which are simple to engineer and can reliably achieve high levels of protein expression. However, plasmids typically require antibiotics for maintenance, and the administration of an antibiotic is often incompatible with in vivo experimentation or treatment. EcN natively contains plasmids pMUT1 and pMUT2, which have no known function but are stable within the bacteria. Here, we describe the development of the pMUT plasmids into a robust platform for engineering EcN for in vivo experimentation, alongside a CRISPR-Cas9 system to remove the native plasmids. We systematically engineered both pMUT plasmids to contain selection markers, fluorescent markers, temperature sensitive expression, and curli secretion systems to export a customizable functional material into the extracellular space. We then demonstrate that the engineered plasmids were maintained in bacteria as the engineered bacteria pass through the mouse GI tract without selection, and that the secretion system remains functional, exporting functionalized curli proteins into the gut. Our plasmid system presents a platform for the rapid development of therapeutic EcN bacteria.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acssynbio.0c00466?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acssynbio.0c00466</a>.Table S1: DNA primers used in this work; Table S2: Sequence of UNS sequences; Table S3: gRNA sequences used in the pFREE and pCryptDel plasmids; Table S4: Variant TlpA* promoter sequences, and their properties; Figure S1: Detailed plasmid maps of pMUT1 and pMUT2; Figure S2: GFP and RFP characterization of engineered pMUT plasmids; Figure S3: Plasmid vectors to cure EcN cryptic plasmids; Figure S4: Curing native pMUT plasmids; Figure S5: In vivo synthetic plasmid loss; Supplementary methods for Figure S5; Figure S6: In vitro growth characterization of bacteria used in vivo (<a class="ext-link" href="/doi/suppl/10.1021/acssynbio.0c00466/suppl_file/sb0c00466_si_001.pdf">PDF</a>)Dataset S1: All data used in the figures (<a class="ext-link" href="/doi/suppl/10.1021/acssynbio.0c00466/suppl_file/sb0c00466_si_002.xlsx">XLSX</a>)Dataset S2: In vivo data (<a class="ext-link" href="/doi/suppl/10.1021/acssynbio.0c00466/suppl_file/sb0c00466_si_003.xlsx">XLSX</a>)This article has not yet been cited by other publications.

Stable expression of HIV-1 MPER extended epitope on the surface of the recombinant probiotic bacteria Escherichia Coli Nissle 1917 using CRISPR/Cas9

Engineered Recombinant Escherichia Coli Probiotic Strains Integrated with F4 and F18 Fimbriae Cluster Genes in the Chromosome and Their Assessment of Immunogenic Efficacy in Vivo.

A long-term stable cold-chain-friendly HIV mRNA vaccine encoding multi-epitope viral protease cleavage site immunogens inducing immunogen-specific protective T cell immunity

Engineered ClearColi™-derived outer membrane vesicles as functional carriers for development of HIV-1 therapeutic vaccine candidate

Expression, Purification, and Renaturation of a Recombinant Peptide-Based HIV Vaccine in Escherichia Coli.

A reverse vaccinology approach to design an mRNA-based vaccine to provoke a robust immune response against HIV-1.

A Recombinant Multi-Epitope Protein MEP1 Elicits Efficient Long-Term Immune Responses Against HIV-1 Infection

Engineering Lactobacillus rhamnosus GG and GR-1 to express HIV-inhibiting griffithsin

Engineering for an HPV 9-Valent Vaccine Candidate Using Genomic Constitutive Over-Expression and Low Lipopolysaccharide Levels in Escherichia Coli Cells

Liposomal Vaccines Incorporating Molecular Adjuvants and Intrastructural T-cell Help Promote the Immunogenicity of HIV Membrane-Proximal External Region Peptides.

Guiding the humoral response against HIV-1 toward a MPER adjacent region by immunization with a VLP-formulated antibody-selected envelope variant

Plasmid Vectors for in Vivo Selection-Free Use with the Probiotic E. coli Nissle 1917

Hiv-1 Gp41 Core with Exposed Membrane-Proximal External Region Inducing Broad Hiv-1 Neutralizing Antibodies

Live Attenuated Salmonella Displaying HIV-1 10E8 Epitope on Fimbriae: Systemic and Mucosal Immune Responses in BALB/c Mice by Mucosal Administration.

Computational approach for identifying immunogenic epitopes and optimizing peptide vaccine through in-silico cloning against Mycoplasma genitalium

The development of HIV vaccines targeting gp41 membrane-proximal external region (MPER): challenges and prospects

Progress on Lactococcus Lactis Expressing Heterologous Antigens As Live Mucosal Vaccines

CRISPR/Cas9 gene editing for the creation of an MGAT1-deficient CHO cell line to control HIV-1 vaccine glycosylation

Evaluation of the immunogenicity of auxotrophic Lactobacillus with CRISPR-Cas9D10A system-mediated chromosomal editing to express porcine rotavirus capsid protein VP4

Engineered dendritic cells-derived exosomes harboring HIV-1 Nef mut -Tat fusion protein and heat shock protein 70: A promising HIV-1 safe vaccine candidate

Evaluation of the Immunity Responses in Mice to Recombinant Bacillus Subtilis Displaying Newcastle Disease Virus HN Protein Truncations